Interon Laboratories, Inc. announced a round of funding on February 10, 2023. The transaction will include participation from new investor, Hanall Biopharma Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34,150 KRW | +3.96% | +8.24% | -22.91% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.91% | 1.26B | |
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B |
- Stock Market
- Equities
- A009420 Stock
- News Hanall Biopharma Co., Ltd.
- Interon Laboratories, Inc. announced that it expects to receive funding from Hanall Biopharma Co., Ltd.